Lineage reports Q2 2026 results, advances COR1 corneal program and OpRegen data
Lineage highlighted three-year OpRegen data, early COR1 manufacturing progress, and a new scientific advisory board, with cash seen lasting into Q3 2028.
Lineage Cell Therapeutics reported its second quarter 2026 results on August 6, 2026, alongside a business update covering its allogeneic cell therapy pipeline.
The company featured positive three-year results from the Phase 1/2a study of RG6501 (OpRegen cell therapy), presented at Foundation Fighting Blindness' Retinal Therapeutics Innovation Summit 2026, suggesting sustained gains in best corrected visual acuity and partial structural retinal restoration, including reappearance of an RPE layer and features associated with photoreceptor recovery.1 Specifically, Cohort 4 patients (12 total, less advanced disease) showed durable treatment effect with mean BCVA scores above baseline at 12, 24, and 36 months.1 Separately, the ongoing Phase 2a GAlette study, run by Roche and Genentech, is open and active at 17 clinical sites in the U.S. and Israel.1
On the preclinical side, Lineage said it used its AlloSCOPE platform to achieve seamless bioreactor-based precursor expansion and differentiation for corneal endothelial cell (CEnC) production for its COR1 program, meeting internal criteria for continued preclinical advancement.1 The company plans to advance COR1 into in-vivo animal testing, with initial preclinical data expected in 2026, targeting Fuchs Endothelial Corneal Dystrophy and Bullous Keratopathy.1
For OPC1, Lineage reported that two administrations using its novel delivery device have been completed in chronic spinal cord injury participants in the DOSED study, with no unexpected procedural, product, or device-related adverse events.1 The company also opened a second DOSED clinical site, Rancho Research Institute, with Rancho Los Amigos National Rehabilitation Center.1
Lineage also established a Scientific Advisory Board with Joachim Fruebis, Ph.D. as founding member.1
On finances, cash, cash equivalents, and marketable securities totaled $50.8 million as of June 30, 2026, which the company expects will support planned operations into the third quarter of 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.